Diosgenin

Name: Diosgenin
Brand: MedChemExpress
SKU: HY-N0177
Rating: 5.0 (6 reviews)

Cat. No.: HY-N0177 Purity: 99.35%: FAQs
Data Sheet SDS COA Handling Instructions Technical Support

Diosgenin, a steroidal saponin, can inhibit STAT3 signaling pathway. Diosgenin is an exogenous activator of Pdia3/ERp57. Diosgenin inhibits aortic atherosclerosis progression by suppressing macrophage miR-19b expression.

For research use only. We do not sell to patients.

Diosgenin Chemical Structure

CAS No. : 512-04-9

Size	Stock	Quantity
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Diosgenin:

Diosgenin glucoside Get quote
Diosgenin (Standard) Get quote

5 Publications Citing Use of MCE Diosgenin

Proliferation Assay

: Diosgenin purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2016;39(4):1626-37. [Abstract]; Arithmetic means ± SEM (n = 10) of erythrocyte annexin-V-binding following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Diosgenin (5-15 µM).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All STAT Isoform Specific Products:

View All Isoforms

STAT3 STAT5 STAT6 STAT1

Biological Activity
Purity & Documentation
References
Customer Review

Description

Diosgenin, a steroidal saponin, can inhibit STAT3 signaling pathway^[1]. Diosgenin is an exogenous activator of Pdia3/ERp57^[2]. Diosgenin inhibits aortic atherosclerosis progression by suppressing macrophage miR-19b expression^[5].

IC₅₀ & Target^[1]

STAT3

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
A549	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
A549	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
A549	IC₅₀	26.41 μM Compound: Diosgenin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
A549	IC₅₀	32.85 μM Compound: DSG; 1	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
ASPC1	IC₅₀	63.11 μM Compound: Diosgenin	Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
BXPC-3	GI₅₀	1 μg/mL Compound: 7	Growth inhibition of humanBxPC3 cells after 48 hrs Growth inhibition of humanBxPC3 cells after 48 hrs	[PMID: 15921418]
DU-145	GI₅₀	8.5 μg/mL Compound: 7	Growth inhibition of human DU145 cells after 48 hrs Growth inhibition of human DU145 cells after 48 hrs	[PMID: 15921418]
GES1	IC₅₀	100.7 μM Compound: Diosgenin	Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HBL-100	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human HBL100 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HBL100 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HCT-116	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HCT-116	IC₅₀	31.41 μM Compound: Diosgenin	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
HCT-116	IC₅₀	49.11 μM Compound: Diosgenin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HeLa	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human HeLa cells after 6 days by SRB assay Cytotoxicity against human HeLa cells after 6 days by SRB assay	[PMID: 22880631]
HepG2	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
HepG2	IC₅₀	> 50 μM Compound: 1, Diosgenin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23153797]
HepG2	IC₅₀	33.87 μM Compound: Diosgenin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HepG2	IC₅₀	48.36 μM Compound: DSG; 1	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
HL-60	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
HT-29	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human HT-29 cells after 6 days by SRB assay Cytotoxicity against human HT-29 cells after 6 days by SRB assay	[PMID: 22880631]
HT-29	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
K562	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human K562 cells after 6 days by SRB assay Cytotoxicity against human K562 cells after 6 days by SRB assay	[PMID: 22880631]
K562	IC₅₀	30.04 μM Compound: DSG; 1	Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
KM-20L2	GI₅₀	1.1 μg/mL Compound: 7	Growth inhibition of human KM20L2 cells after 48 hrs Growth inhibition of human KM20L2 cells after 48 hrs	[PMID: 15921418]
MCF7	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
MCF7	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
MCF7	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human MCF7 cells after 6 days by SRB assay Cytotoxicity against human MCF7 cells after 6 days by SRB assay	[PMID: 22880631]
MCF7	GI₅₀	0.42 μg/mL Compound: 7	Growth inhibition of human MCF7 cells after 48 hrs Growth inhibition of human MCF7 cells after 48 hrs	[PMID: 15921418]
MCF7	IC₅₀	23.91 μM Compound: Diosgenin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
MCF7	IC₅₀	28.52 μM Compound: DSG; 1	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
MDA-MB-231	IC₅₀	> 50 μM Compound: 1, Diosgenin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23153797]
MKN-45	IC₅₀	78.32 μM Compound: DSG; 1	Cytotoxicity against human MNK45 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MNK45 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
MM96L	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human MM96L cells after 6 days by SRB assay Cytotoxicity against human MM96L cells after 6 days by SRB assay	[PMID: 22880631]
NCI-H358	IC₅₀	> 40 μM Compound: Diosgenin	Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
NCI-H460	IC₅₀	> 50 μM Compound: 1	Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay	[PMID: 28606759]
NCI-H460	GI₅₀	1.6 μg/mL Compound: 7	Growth inhibition of human NCI-H460 cells after 48 hrs Growth inhibition of human NCI-H460 cells after 48 hrs	[PMID: 15921418]
NFF	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human NFF cells after 6 days by SRB assay Cytotoxicity against human NFF cells after 6 days by SRB assay	[PMID: 22880631]
P388	ED₅₀	> 10 μg/mL Compound: 7	Growth inhibition of mouse P388 cells after 48 hrs Growth inhibition of mouse P388 cells after 48 hrs	[PMID: 15921418]
SF-268	GI₅₀	1.6 μg/mL Compound: 7	Growth inhibition of human SF268 cells after 48 hrs Growth inhibition of human SF268 cells after 48 hrs	[PMID: 15921418]
SMMC-7721	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
SW480	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
SW-620	IC₅₀	> 40 μM Compound: Diosgenin	Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
T-24	IC₅₀	28.85 μM Compound: DSG; 1	Cytotoxicity against human T24 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human T24 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
THP-1	IC₅₀	6.96 μM Compound: 2	Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs	[PMID: 20561785]

In Vitro

In MC65 cells, a cellular AD model, diosgenin exhibited weak protective abilities at 1 μM, may represent a good candidate as a steroidal moiety in our bivalent compounds against AD pathology^[3]. Diosgenin inhibits the constitutive activation of STAT3 in C3A cells in a dose-dependent manner, with maximum inhibition occurring at around 100 μM^[1].
Diosgenin (10 μM; 24 h) significantly decreases the levels of miR-19b in foam cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Diosgenin treatment significantly reduces fasted and refed blood glucose level in HF dietfed mice. Diosgenin treatment significantly reduces blood glucose level in IPGTT test, compared with that of HF diet-fed mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

414.62

Formula

C₂₇H₄₂O₃

CAS No.

512-04-9

Appearance

Solid

Color

White to off-white

SMILES

O[C@]1([H])CC2=CC[C@]3([H])[C@@](CC[C@@]4(C)[C@@]3([H])C[C@@]5([H])[C@]4([H])[C@@](C)([H])[C@@]6(CC[C@@]([H])(C)CO6)O5)([H])[C@@]2(C)CC1

Structure Classification

Steroids

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

Ethanol : 3.33 mg/mL (8.03 mM; Need ultrasonic)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4118 mL	12.0592 mL	24.1185 mL
5 mM	0.4824 mL	2.4118 mL	4.8237 mL
10 mM	---	---	---

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.67 mg/mL (1.62 mM); Clear solution

This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (6.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.67 mg/mL (1.62 mM); Clear solution

This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (6.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 0.67 mg/mL (1.62 mM); Clear solution

This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (6.7 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil
Solubility: 2.5 mg/mL (6.03 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 15% Solutol HS 15 10% Cremophor EL 35% PEG400 40% Water
Solubility: 10.31 mg/mL (24.87 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.35%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (252 KB) HNMR (264 KB) RP-HPLC (253 KB) MS (83 KB)

Handling Instructions (2659 KB)

References

[1]. Li F, et al. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 2010 Jun 28;292(2):197-207. [Content Brief]

[2]. Tohda C, et al. Diosgenin is an exogenous activator of 1,25D₃-MARRS/Pdia3/ERp57 and improves Alzheimer's disease pathologies in 5XFAD mice. Sci Rep. 2012;2:535. [Content Brief]

[3]. Jeremy E. Chojnacki, et al. Bivalent ligands incorporating curcumin and diosgenin as multifunctional compounds against Alzheimer’s disease. Bioorganic & Medicinal Chemistry, 23 (2015) 7324–7331 [Content Brief]

[4]. Wang X, et al. Effect of diosgenin on metabolic dysfunction: Role of ERβ in the regulation of PPARγ. Toxicol Appl Pharmacol. 2015 Dec 1;289(2):286-96. [Content Brief]

[5]. Yun-cheng Lv, et al. Diosgenin Inhibits Atherosclerosis via Suppressing the MiR-19b-induced Downregulation of ATP-binding Cassette Transporter A1. Atherosclerosis, 2014, 240(1), 80-89.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol	1 mM	2.4118 mL	12.0592 mL	24.1185 mL	60.2962 mL
Ethanol	5 mM	0.4824 mL	2.4118 mL	4.8237 mL	12.0592 mL

Diosgenin Related Classifications

Metabolic Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Diosgenin512-04-9STATMicroRNAmiRNAInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Diosgenin

Customer Review

Other Forms of Diosgenin:

Diosgenin Related Antibodies

5 Publications Citing Use of MCE Diosgenin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All STAT Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Diosgenin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Diosgenin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report